Published in Lancet on March 04, 2015
Prospective Electronic Polygenic Risk Study (PEPRS1) | NCT05072275
Prospective Electronic Polygenic Risk Study - Second Phase (PEPRS2) | NCT05175651
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med (2016) 3.68
Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J (2015) 1.65
Genomic prediction of coronary heart disease. Eur Heart J (2016) 1.49
Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet (2016) 1.05
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation (2016) 0.97
Statin treatment: can genetics sharpen the focus? Lancet (2015) 0.89
Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol (2015) 0.89
Atherosclerosis: Successes, Surprises, and Future Challenges. Circ Res (2016) 0.86
Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol (2015) 0.84
The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med (2016) 0.83
Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J (2016) 0.82
Polygenic Risk Score Identifies Subgroup with Higher Burden of Atherosclerosis and Greater Relative Benefit from Statin Therapy in the Primary Prevention Setting. Circulation (2017) 0.82
Association of six CpG-SNPs in the inflammation-related genes with coronary heart disease. Hum Genomics (2016) 0.81
The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79
Marginal role for 53 common genetic variants in cardiovascular disease prediction. Heart (2016) 0.79
LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. Circ Res (2016) 0.79
Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet (2017) 0.76
Moving From Digitalization to Digitization in Cardiovascular Care: Why Is it Important, and What Could it Mean for Patients and Providers? J Am Coll Cardiol (2015) 0.76
Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts. Atherosclerosis (2015) 0.76
Effect of diet on mortality and cancer recurrence among cancer survivors: a systematic review and meta-analysis of cohort studies. Nutr Rev (2016) 0.75
A Genetic Risk Score Is Associated with Weight Loss Following Roux-en Y Gastric Bypass Surgery. Obes Surg (2016) 0.75
Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. Circ Cardiovasc Genet (2017) 0.75
Reducing Cardiovascular Risk Using Genomic Information in the Era of Precision Medicine. Circulation (2016) 0.75
[Less (pulmonary embolism) recurrence through longer oral anticoagulation]. Dtsch Med Wochenschr (2015) 0.75
Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis. Circ Cardiovasc Genet (2016) 0.75
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics J (2016) 0.75
Genetics: Genetic risk scores--new promises for drug evaluation. Nat Rev Cardiol (2015) 0.75
Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease? Glob Cardiol Sci Pract (2015) 0.75
Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? J Clin Med (2016) 0.75
Metabolic Mediators of the Effects of Family History and Genetic Risk Score on Coronary Heart Disease-Findings From the Malmö Diet and Cancer Study. J Am Heart Assoc (2017) 0.75
Effect of Disclosing Genetic Risk for Coronary Heart Disease on Information Seeking and Sharing: The MI-GENES Study (Myocardial Infarction Genes). Circ Cardiovasc Genet (2017) 0.75
21st Century Diseases: Commonly Rare and Rarely Common? Antioxid Redox Signal (2017) 0.75
Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Curr Atheroscler Rep (2017) 0.75
Comparing distributions of polygenic risk scores of type 2 diabetes and coronary heart disease within different populations. PLoS One (2017) 0.75
Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. J Am Heart Assoc (2017) 0.75
Precision reproductive medicine: multigene panel testing for infertility risk assessment. J Assist Reprod Genet (2017) 0.75
The promise of stromal cell-derived factor-1 in novel heart disease treatments. J Mol Med (Berl) (2017) 0.75
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med (1994) 7.47
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
Lifetime risks of cardiovascular disease. N Engl J Med (2012) 5.95
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med (1993) 5.35
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 2.12
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil (2010) 1.98
Genetics of human cardiovascular disease. Cell (2012) 1.90
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur Heart J (2010) 1.90
A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet (2012) 1.81
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J (2012) 1.75
Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis. J Am Coll Cardiol (2014) 1.61
Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol (2013) 1.32
A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis (2012) 1.21
Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem (2006) 1.19
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis (2011) 1.18
Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol (2009) 1.15
Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.13
Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One (2012) 1.13
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol (2002) 1.12
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics (2008) 1.12
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arterioscler Thromb Vasc Biol (2006) 1.07
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol (2008) 1.03
KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis (2011) 0.96
Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. Eur Heart J (2012) 0.95
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Hum Genet (2010) 0.95
The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. Eur Heart J (2013) 0.94
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenet Genomics (2009) 0.91
Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J (2007) 0.86
Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J (2013) 0.86
Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One (2012) 0.84